AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33230077
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) bi-weekly for 6 weeks
Trial: 35238476
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous ornithine phenylacetate (OP)
Trial: 33818978
Drug: Weekly injection
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injection (more effective)
Trial: 33818978
Drug: Weekly injection
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injection with decoy
Trial: 33818978
Drug: Every-three-month injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every-three-month injection with decoy
Trial: 32600400
Drug: Internet-based psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based psychodynamic treatment (IPDT)
Trial: 39445776
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg
Trial: 39141364
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg
Trial: 34545652
Drug: Controlled-release dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release dinoprostone vaginal delivery system (PROPESS)
Trial: 32246662
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin ointment
Trial: 33188584
Drug: 1% DCI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% DCI, 0.25% DCI, vehiculum without active agent
Trial: 33037320
Drug: H4:IC31 (subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H4:IC31 (subunit vaccine containing Ag85B and TB10.4)
Trial: 33037320
Drug: BCG (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (live attenuated vaccine)
Trial: 35674488
Drug: EDS-FLU 186
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS-FLU 186 μg
Trial: 35674488
Drug: EDS-FLU 372
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS-FLU 372 μg (prior ESS)
Trial: 35674488
Drug: EDS-FLU 186
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS-FLU 186 μg (unoperated)
Trial: 35674488
Drug: EDS-FLU 372
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS-FLU 372 μg (unoperated)
Trial: 34418958
Drug: Receiving the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving the results of a SARS-CoV-2 antibody test
Trial: 33370007
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine (perceived)
Trial: 33370007
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (perceived)
Trial: 33689730
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at 6 L/min for 6‐12 hours
Trial: 32099328
Drug: Ovidrel® (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovidrel® (reference drug)
Trial: 32099328
Drug: LZM003 (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LZM003 (test drug)
Trial: 36273216
Drug: Phenytoin 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 10% cream
Trial: 34667404
Drug: Propranolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol plus conventional therapy
Trial: 39181597
Drug: Semaglutide 2·4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 2·4 mg
Trial: 33556413
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 19)
Trial: 33139710
Drug: Nimodipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (60 mg single oral dose)
Trial: 33980290
Drug: Gratitude journal
RxNorm normalized name: Journavx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gratitude journal intervention (logging 5 things they felt grateful for daily for 2 weeks)
Trial: 33980290
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily self-evaluations only)
Trial: 33909357
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (50 mg once daily)
Trial: 36571569
Drug: ticagrelor/aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor/aspirin
Trial: 36571569
Drug: clopidogrel/aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel/aspirin
Trial: 34432984
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (ICBT) for tinnitus
Trial: 39208825
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard therapy
Trial: 32527346
Drug: Xuebijing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing 100 mL group
Trial: 34579741
Drug: Anisodamine (0.1-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine (0.1-0.5 mg/kg/hour)
Trial: 35250582
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with honeysuckle before rash occurred (Arm A)
Trial: 35250582
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment with honeysuckle when rash occurred (Arm B)
Trial: 34292474
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment blood pressure target of 140–179 mm Hg
Trial: 33952195
Drug: Group-sequential two-arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-sequential two-arm trials
Trial: 38454079
Drug: Aripiprazole augmentation
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole augmentation
Trial: 34370925
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy interventions for daily activities and quality of life
Trial: 32947434
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2)
Trial: 34431493
Drug: LLF580 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLF580 300 mg subcutaneously every 4 weeks for 3 doses
Trial: 32584117
Drug: Waitlist (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist (before treatment)
Trial: 34376233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of default strategy and accountable justification strategy within flowsheet documentation
Trial: 33185167
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of Platelet Rich Plasma (PRP), 3 injections at monthly intervals.
Trial: 33185167
Drug: Single intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of steroid.
Trial: 37674551
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRET)
Trial: 33895322
Drug: GRAd-COV2 vaccine
RxNorm normalized name: GRAd-COV2
DrugBank: GRAd-COV2 (DB16428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAd-COV2 vaccine
Trial: 34943312
Drug: Low-dose, high-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, high-frequency simulation training
Trial: 34943312
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least monthly training
Trial: 32065984
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT), n = 17
Trial: 34982820
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed oil (SSO) therapy
Trial: 32271833
Drug: READY for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: READY for MS (resilience group training program based on Acceptance and Commitment Therapy)
Trial: 34843141
Drug: Standardised milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised milk-based formulation (SMBF)
Trial: 34843141
Drug: Standardised non-milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised non-milk based formulation (SNMBF)
Trial: 34843141
Drug: Hospital-based formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based formulation (HBF)
Trial: 36321244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NAC + ALA
Trial: 34404592
Drug: Maintaining serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintaining serum potassium at ≥3.6 mEq/L
Trial: 37221146
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept
Trial: 33506805
Drug: Biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatment (ACS)
Trial: 33506805
Drug: Biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatment (PRP)
Trial: 33506805
Drug: Physical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical treatment (CM)
Trial: 34076382
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine using buccal infiltration
Trial: 35476650
Drug: RSVpreF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF vaccine (120 or 240 μg, with or without aluminum hydroxide)
Trial: 35476650
Drug: RSVpreF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF vaccine (with aluminum hydroxide)
Trial: 35476650
Drug: RSVpreF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF vaccine (without aluminum hydroxide)
Trial: 35662486
Drug: Hydromorphone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.2 mg bolus via PCA)
Trial: 35662486
Drug: Morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2 mg bolus via PCA)
Trial: 32919400
Drug: Active NeuroStar
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active NeuroStar TMS monotherapy (n=48)
Trial: 34324042
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg TXA
Trial: 34324042
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg normal saline (placebo)
Trial: 32949787
Drug: SRP followed
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP followed by single subgingival application of 1.2 % simvastatin gel (SMV group)
Trial: 35594542
Drug: Dual pathway
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin
Trial: 35447283
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy followed by pre-operative chemotherapy (EXP)
Trial: 35447283
Drug: Chemoradiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy and optional post-operative chemotherapy (STD)
Trial: 35447283
Drug: Chemoradiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy and optional post-operative chemotherapy (STD+)
Trial: 35447283
Drug: Chemoradiotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy without post-operative chemotherapy (STD-)
Trial: 34221478
Drug: Parental knowledge
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental knowledge regarding antibiotic use for URTIs
Trial: 34221478
Drug: Parental practices
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental practices regarding antibiotic prescriptions
Trial: 35172876
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water injections (6 injections of sterile water, 0.1-0.3 ml per injection)
Trial: 34500174
Drug: 30 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 hours of auditory-based targeted cognitive training (TCT) + treatment-as-usual (TAU)
Trial: 35020047
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) + episodic future thinking (EFT) + contingency management
Trial: 39111953
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg twice daily
Trial: 32306485
Drug: PE plus
RxNorm normalized name: Acetaminophen/Phenylephrine Hydrochloride 500 MG-5 MG Oral Tablet [ORANYL PE PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE plus sertraline
Trial: 39305459
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy
Trial: 32820619
Drug: Single-dose apararenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose apararenone (5-320 mg)
Trial: 32820619
Drug: Single-dose apararenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose apararenone (160 or 640 mg)
Trial: 32820619
Drug: Eplerenone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (200 mg)
Trial: 32600078
Drug: CRP >100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP >100 mg/L
Trial: 32600078
Drug: Lactate dehydrogenase
RxNorm normalized name: Lactate dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate dehydrogenase >300 U/L
Trial: 32896753
Drug: Standard breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard breast cancer treatment
Trial: 36404704
Drug: Antibiotic resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic resistance condition
Trial: 34371907
Drug: 1 cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cup of espresso coffee plus two cocoa-based products containing coffee (PC) twice per day for 1 month
Trial: 35771315
Drug: Dexmedetomidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine plus ropivacaine (25 mL of 0.3% ropivacaine + 1 μg/kg dexmedetomidine)
Trial: 35771315
Drug: Ropivacaine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (25 mL of 0.3% ropivacaine)
Trial: 33340432
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g eicosapentaenoic acid (EPA) plus 1 g docosahexaenoic acid (DHA)
Trial: 32664057
Drug: Acetaminophen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,000 mg/d)
Trial: 32931029
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment L+RT
Trial: 32931029
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment M+RT
Trial: 36399712
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg leniolisib twice daily for 12 weeks
Trial: 36727855
Drug: NOL-guided fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NOL-guided fentanyl administration
Trial: 35831797
Drug: TXA retrograde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA retrograde injection (TXA-RI)
Trial: 35831797
Drug: TXA-soaked absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA-soaked absorbable Gelfoam (TXA-Gel)
Trial: 33739127
Drug: 3-month aspirin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month aspirin therapy with continued ticagrelor
Trial: 33739127
Drug: 12-month aspirin
RxNorm normalized name: aspirin / menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month aspirin and ticagrelor
Trial: 39222277
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily)
Trial: 35441464
Drug: Opioid analgesic
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesic prescription at hospital discharge
Trial: 35441464
Drug: Opioid analgesic
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesic use 4 weeks after ED presentation
Trial: 34020962
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg two times per day)
Trial: 34020962
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules two times per day)
Trial: 35661954
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no locoregional therapy)
Trial: 32738479
Drug: 7.5-μg vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-μg vaccine
Trial: 32738479
Drug: 15-μg vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-μg vaccine
Trial: 32738479
Drug: 30-μg vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated 30 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-μg vaccine
Trial: 36412015
Drug: Yeahhh Baby!®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeahhh Baby!® ointment
Trial: 33573421
Drug: Local pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local pain (Capsaicin gel applied)
Trial: 33573421
Drug: Remote pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote pain (Capsaicin gel applied)
Trial: 35271958
Drug: Concentric circle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentric circle method, 10 mL
Trial: 35271958
Drug: Back-and-forth friction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back-and-forth friction method, 3 mL
Trial: 35271958
Drug: Back-and-forth friction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back-and-forth friction method, 10 mL
Trial: 32616489
Drug: Impryl (nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impryl (nutritional supplement)
Trial: 35802374
Drug: Exercise-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-based physical therapy
Trial: 32336038
Drug: Lenabasum (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum (5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks)
Trial: 32729217
Drug: First-generation standard-of-care
RxNorm normalized name: First-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation standard-of-care basal insulin analogues (SOC‐BI; insulin glargine 100 U/mL or insulin detemir)
Trial: 35096104
Drug: NXT15906F6 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXT15906F6 (250 mg/day)
Trial: 35096104
Drug: NXT19185 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXT19185 (300 mg/day)
Trial: 34221932
Drug: Fibrinogen intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen intra-articular injection
Trial: 32103514
Drug: 8-mg intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg intravenous dexamethasone
Trial: 35722590
Drug: Metacognitive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Therapy (MCT)
Trial: 34656207
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (direct-to-injection group)
Trial: 34656207
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (oral lead-in group)
Trial: 34656207
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care oral regimen (control group)
Trial: 32460712
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose regimen of Mebendazole (100 mg twice a day for three consecutive days)